However, in a report published on Monday to "restore this" negative view ", HAS has a" #; proposes to increase "fundraising" funding support for innovation, which is currently in place; support them.
She "recognizes the value of these tests as a decision maker", but "he considers it necessary to keep a clinical examination".
So he wants a comparative study of the four tests available and that this clinical study "worries" the number of best patients who will benefit, or 2,000 to 4,000 woman each year according to the figures we can do "identified to AFP Cédric Carbonneil, head of a professional activity department at the HAS.
The HAS "reconsider its feedback back when it passes this data".
The tests in a question called "genomic signatures" – Mammaprint, Oncolype Dx, Prosigna and Endopredict – assess the risk by a group of genes involved in developing the tumor from a sample off. Around 4,500 tests were carried out in 2017 as part of the innovative activities.
Breast cancer, with 55,000 new cases a year, is the most common cancer among women, and remembers the HAS.
The remedies are varied to many types of therapies (surgery, radiotherapy, chemotherapy, hormonotherapy). The degree, the advanced (meter-meter) degree or not, and the tumor symptoms (for example hormonal treatment sensitive) are included.
In most instances, healthcare teams have enough elements to decide on the establishment of cemotherapy after post-work, not to do so; Going into this test, Judge HAS.
The HAS specifically describes the number of females (tumor 1 to 5 cm, aware of hormone cure, non-infected or infected garrison …) and these genetic tests would be useful . This equals to "5% to 10% of the 40,000 local financial cancer," said Mr Carbonneil.
According to different studies, for a woman in five or one in four, the decision to make advanced chemotherapy is different according to the test being used, and mentions the HAS among its critics.
"Nearly 10,000 women in France have benefited from these tests in the last three years," according to Professor Pascal Pujol, President of the French Medical and Medical Medicine Association (SFMPP), who agree to the situation of the HAS.
This learning society, which is similar to HAS experts, believes that recent international surveys have been launched. Providing sufficient level of evidence to restore feedback. Despite this, "SFMPP is pleased that HAS allows women to access these tests by seeking to expand their funding in a new context, abuse, "he says.
"We'll do too much chemotherapy in France," says Roman Roman Catholic at Curie Institute at the beginning of the application that received unsure funding for those tests that are being examined. used for "de-escalation".
"Obviously avoiding unnecessary remedies is a huge benefit." "It's better to keep the exam finances, it will add this specialist, at least, as a controller to use them wisely.